Agenus Inc. Appoints New CMO, Elects Director
Ticker: AGEN · Form: 8-K · Filed: Nov 5, 2024 · CIK: 1098972
Sentiment: neutral
Topics: management-change, board-election, compensation
TL;DR
Agenus Inc. just hired a new CMO and added a director to the board. Big changes coming?
AI Summary
On October 30, 2024, AGENUS INC. announced the appointment of Dr. David E. Johnson as Chief Medical Officer and the election of Ms. Sarah Chen to its Board of Directors. Dr. Johnson's appointment is effective November 4, 2024, and Ms. Chen's election is effective immediately. The company also disclosed compensatory arrangements for its officers.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member can signal strategic shifts or new directions for the company's medical and governance strategies.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty and potential shifts in strategy, impacting the company's future performance.
Key Players & Entities
- AGENUS INC. (company) — Registrant
- Dr. David E. Johnson (person) — Appointed Chief Medical Officer
- Ms. Sarah Chen (person) — Elected to Board of Directors
- November 4, 2024 (date) — Effective date of Dr. Johnson's appointment
- October 30, 2024 (date) — Date of the earliest event reported
FAQ
Who is the new Chief Medical Officer for AGENUS INC.?
Dr. David E. Johnson has been appointed as the new Chief Medical Officer for AGENUS INC., with his appointment effective November 4, 2024.
When is Dr. David E. Johnson's appointment effective?
Dr. David E. Johnson's appointment as Chief Medical Officer is effective November 4, 2024.
Who has been elected to AGENUS INC.'s Board of Directors?
Ms. Sarah Chen has been elected to AGENUS INC.'s Board of Directors, effective immediately.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing is dated October 30, 2024.
What other information is disclosed regarding officers in this filing?
The filing also discloses compensatory arrangements for certain officers of AGENUS INC.
Filing Stats: 466 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-11-05 16:05:07
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share AGEN The Nasdaq
Filing Documents
- agen-20241030.htm (8-K) — 35KB
- 0000950170-24-121443.txt ( ) — 142KB
- agen-20241030.xsd (EX-101.SCH) — 23KB
- agen-20241030_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 5, 2024 By: /s/ Garo H. Armen Garo H. Armen, Chairman and CEO